Omalizumab Biosimilar Matches Reference Product in Chronic Spontaneous Urticaria
June 24th 2025
By Skylar Jeremias
ArticleCT-P39, an omalizumab biosimilar, shows comparable efficacy and safety to the original in treating chronic spontaneous urticaria, enhancing patient access.